Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
Michael Z Liao,1 Johannes Kast,1 Marloes Berkhout,2 Hans Prenen,3 Sandeep Dutta,4 Vijay V Upreti1 1Clinical Pharmacology, Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA; 2Amgen B.V., Breda, the Netherlands; 3Antwerp University Hospital, Edegem, Belgium; 4Clinical Pharmacolog...
Enregistré dans:
Auteurs principaux: | Liao MZ, Kast J, Berkhout M, Prenen H, Dutta S, Upreti VV |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/25ece9ce343c4273bcedfe4dba212823 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
par: Hendrikx JJMA, et autres
Publié: (2020) -
Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan
par: Muhammad Muaaz Munir, et autres
Publié: (2021) -
Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis
par: Chuhui Wang, et autres
Publié: (2021) -
Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses
par: Manjunath P. Pai, et autres
Publié: (2021) -
Estimating the no-observed-adverse-effect-level (NOAEL) of hormetic dose-response relationships in meta-data evaluations
par: Evgenios Agathokleous, et autres
Publié: (2021)